Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.67 |
| ▸ | MELK | Q14680 | 1/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874209 | 1.00 | BCL6 (0.67) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267604 | 0.91 | BCL6 (0.70) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL29873779 | 0.89 | BCL6 (0.63) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23250027 | 0.89 | BCL6 (0.63) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL20284344 | 0.88 | BCL6 (0.70) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267253 | 0.87 | BCL6 (0.76) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL31554638 | 0.86 | BCL6 (0.75) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL20284725 | 0.86 | BCL6 (0.79) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL20284547 | 0.86 | BCL6 (0.74) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL22932328 | 0.85 | BCL6 (0.78) | BCL6NCOR2MELKCHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | BCL6 1/4885NCOR2 640/4885MELK 446/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | BCL6 1/4885NCOR2 640/4885MELK 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.